☆ 4.6 Article

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)

BMC CANCER (2023)

Related references

Note: Only part of the references are listed.

Article

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India

Dharna Gupta et al.

JCO Global Oncology (2023)

Add to Collection

Review Oncology

Clinical Review on the Management of Metastatic Renal Cell Carcinoma

Jennifer Tran et al.

Summary: Renal cell carcinomas show significant variations in tumor biology and disease progression, resulting in diverse treatment paradigms. Combination therapies have become the standard of care for most patients with metastatic renal cell carcinoma. This review highlights recent crucial data that have led to changes in treatment approaches and provides a practical framework for managing patients with mRCC.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection

Review Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

Borje Ljungberg et al.

Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.

EUROPEAN UROLOGY (2022)

Add to Collection

Review Oncology

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Yu-Wei Chen et al.

Summary: This review discusses the landmark trials and treatment options for metastatic clear cell renal cell carcinoma (mccRCC). Four immuno-oncology (IO)-based combinations, including IO/IO and IO/TKI, have shown overall survival benefit, but each has distinct efficacy and toxicity profiles. Factors such as patient tumor burden, performance status, and risk group influence the choice of IO-based treatment. Future studies should focus on identifying biomarkers to improve patient outcomes.

CURRENT ONCOLOGY REPORTS (2022)

Add to Collection

Review Oncology

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

Aly-Khan A. Lalani et al.

Summary: First-line immune checkpoint inhibitor (ICI) combination therapy has demonstrated significant survival benefits for renal cell carcinoma (RCC) patients, highlighting the importance of global access to these treatment options.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

T. Powles et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Urology & Nephrology

The role of immunotherapy in advanced renal cell carcinoma

Ercilia Rita Mondlane et al.

INTERNATIONAL BRAZ J UROL (2021)

Add to Collection

Article Oncology

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

Michael R. Harrison et al.

Summary: Systemic therapy can be deferred in patients with metastatic renal cell carcinoma and slow-growing metastases. Active surveillance is a common and safe alternative to immediate systemic therapy for selected patients, leading to better quality of life outcomes compared to those who receive systemic therapy.

CANCER (2021)

Add to Collection

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

R. Kanesvaran et al.

Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.

ESMO OPEN (2021)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

Brian I. Rini et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

New approaches to first-line treatment of advanced renal cell carcinoma

Daniel J. George et al.

Summary: The treatment of patients with renal cell carcinoma (RCC) is rapidly evolving, with promising new regimens such as the combination of tyrosine kinase inhibitors with immune checkpoint inhibitors. Various systemic first-line treatments have been approved for clear cell RCC, targeting different risk levels of patients, showing positive results. Efforts are also being made to identify biomarkers to guide treatment decisions.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

Juhani Knuuti et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Medicine, Research & Experimental

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis

Kirsi M. Manz et al.

ADVANCES IN THERAPY (2020)

Add to Collection

Article Oncology

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

T.K. Choueiri et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Medicine, Research & Experimental

Research progress on advanced renal cell carcinoma

Xin-da Song et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)

Add to Collection

Review Oncology

The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review

Shouki Bazarbashi et al.

FUTURE ONCOLOGY (2020)

Add to Collection

Article Urology & Nephrology

Sequencing Therapies for Metastatic Renal Cell Carcinoma

Nazli Dizman et al.

UROLOGIC CLINICS OF NORTH AMERICA (2020)

Add to Collection

Review Urology & Nephrology

Sarcomatoid renal cell carcinoma: biology, natural history and management

Kyle A. Blum et al.

NATURE REVIEWS UROLOGY (2020)

Add to Collection

Article

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma

Annalisa Guida et al.

Oncotarget (2020)

Add to Collection

Article Oncology

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albiges et al.

ESMO OPEN (2020)

Add to Collection

Review Oncology

Epidemiology of Renal Cell Carcinoma

Sandeep Anand Padala et al.

WORLD JOURNAL OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Huan Deng et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

Sumanta Pal et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma

Kazutaka Okita et al.

CLINICAL GENITOURINARY CANCER (2019)

Add to Collection

Article Oncology

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

Robert J. Motzer et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Editorial Material Medicine, General & Internal

Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?

Megan R. Haymart et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Oncology

Treatment of renal cell carcinoma: Current status and future directions

Pedro C. Barata et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2017)

Add to Collection

Article Oncology

Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis

Hendrik Eggers et al.

JOURNAL OF KIDNEY CANCER AND VHL (2017)

Add to Collection

Review Urology & Nephrology

First-line treatment options in metastatic renal cell cancer

Anil Kapoor

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2016)

Add to Collection

Article Oncology

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

Brian I. Rini et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Urology & Nephrology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy

Allard Noe et al.

WORLD JOURNAL OF UROLOGY (2016)

Add to Collection

Review Oncology

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Pooja Ghatalia et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)

Add to Collection

Article Oncology

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Robert J. Motzer et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Otorhinolaryngology

Clinical Consensus Statement: Tracheostomy Care

Ron B. Mitchell et al.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2013)

Add to Collection

Article Oncology

How to select amongst available options for the treatment of advanced RCC?

B. Escudier et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Oncology

Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors

Robert J. Motzer et al.

CANCER (2010)

Add to Collection

Review Urology & Nephrology

Advances in renal cell carcinoma treatment

Marc-Oliver Grimm et al.

THERAPEUTIC ADVANCES IN UROLOGY (2010)

Add to Collection

Article Oncology

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

TM Mekhail et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.